Prof San Miguel, Prof Philippe Moreau, Prof Antonio Palumbo, Prof Meletios Dimopoulos and Prof Thierry Facon discuss the important developments in the treatment of multiple myeloma (MM) presented at ASH 2011, at the Post ASH meeting in Paris. They cover the impact of new MM data on clinical practice and the updates in front-line treatment in both transplant and non-transplant settings. They finish by looking at the next steps in MM treatment. The VISTA study, lenalidomide, bortezomib, melphalan-prednisone and novel proteasome inhibitor MLN9708 are all covered.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).